Page last updated: 2024-12-07

benzyldihydronicotinamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benzyldihydronicotinamide (BNAH) is a reduced form of nicotinamide adenine dinucleotide (NADH) that is often used as a hydride donor in organic synthesis. It is a powerful reducing agent that can be used to reduce a variety of functional groups, including ketones, aldehydes, and imines. BNAH is typically prepared by the reduction of nicotinamide with sodium borohydride. It is a stable compound that can be stored at room temperature for extended periods. BNAH is a useful reagent for the synthesis of a wide range of organic compounds, including pharmaceuticals, natural products, and agrochemicals. It is also studied for its potential use in biocatalysis and in the development of new therapeutic agents.'

benzyldihydronicotinamide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID95276
CHEMBL ID25718
SCHEMBL ID2205423
MeSH IDM0040178

Synonyms (42)

Synonym
CBMICRO_010868
AKOS015839161
nsc-26899
1-benzyl-1,4-dihydronicotinamide
3-pyridinecarboxamide,4-dihydro-1-(phenylmethyl)-
952-92-1
n-benzyl-1,4-dihydronicotinamide
nsc26899
1,4-dihydro-n-1-benzylnicotinamide
benzyldihydronicotinamide
BIM-0010813.P001
B1156
CHEMBL25718 ,
FT-0662746
1-benzyl-4h-pyridine-3-carboxamide
1-benzyl-1,4-dihydro-pyridine-3-carboxamide
nsc 26899
3-pyridinecarboxamide, 1,4-dihydro-1-(phenylmethyl)-
1-benzyl-3-carbamido-1,4-dihydropyridine
nicotinamide, 1-benzyl-1,4-dihydro-
hsu8ja8rmp ,
unii-hsu8ja8rmp
CB14249
smsf0003808
1-benzyl-1,4-dihydro-nicotinamide
1,4-dihydro-1-(phenylmethyl)-3-pyridinecarboxamide
n-benzyl-3-carbamoyl-1,4-dihydropyridine
bnah
SCHEMBL2205423
DTXSID90241783
mfcd00059769
AS-63545
bdbm50481404
CMNUYDSETOTBDE-UHFFFAOYSA-N
1-benzyl-1,4-dihydropyridine-3-carboxamide
1,4-dihydro-n-benzylnicotinamide
1-benzyl-3-carbamoyl-1,4-dihydropyridine
(4-ethylphenyl)-(4-n-propylphenyl)ethyne
1-benzyl-1,4-dihydronicotinamide , 95%
AMY31830
CS-0119922
SY053616
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Genome polyproteinDengue virus 2 Puerto Rico/PR159-S1/1969IC50 (µMol)62.65001.52005.50009.4600AID458603; AID458604
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID76982Inhibition of muscarinic receptor mediated [Ca2+] dependent contraction of guinea pig ileal longitudinal smooth muscle; No data1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Crystal structures and pharmacological activity of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-(unsubstituted, 2-methyl-, 4-methyl-, 3-nitro-, 4-nitro-, and 2,4-dinitrophenyl)-1,4-dihydropyridine.
AID458604Inhibition of Dengue virus type 2 NS5 RNA methyltransferase SAM site2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid.
AID458603Inhibition of Dengue virus type 2 NS5 RNA methyltransferase SAM site with 0.1 % TX1002010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
Novel inhibitors of dengue virus methyltransferase: discovery by in vitro-driven virtual screening on a desktop computer grid.
AID77342Calcium channel antagonistic activity relative to 2,6-Dimethyl-4-(2-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid dimethyl ester(=100); No data1982Journal of medicinal chemistry, Feb, Volume: 25, Issue:2
Crystal structures and pharmacological activity of calcium channel antagonists: 2,6-dimethyl-3,5-dicarbomethoxy-4-(unsubstituted, 2-methyl-, 4-methyl-, 3-nitro-, 4-nitro-, and 2,4-dinitrophenyl)-1,4-dihydropyridine.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (10.53)18.7374
1990's0 (0.00)18.2507
2000's8 (42.11)29.6817
2010's7 (36.84)24.3611
2020's2 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.29 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]